Get the Stockscreener App
41.23
4.78%
1.88
After Hours:
41.28
0.05
+0.12%
Procept Biorobotics Corp stock is traded at $41.23, with a volume of 727.01K.
It is up +4.78% in the last 24 hours and down -29.83% over the past month.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
See More
Previous Close:
$39.35
Open:
$39.87
24h Volume:
727.01K
Relative Volume:
0.69
Market Cap:
$2.29B
Revenue:
$249.12M
Net Income/Loss:
$-90.19M
P/E Ratio:
-24.25
EPS:
-1.7
Net Cash Flow:
$-88.21M
1W Performance:
-0.87%
1M Performance:
-29.83%
6M Performance:
-33.77%
1Y Performance:
-48.64%
1-Day Range:
$39.27
$41.42
1-Week Range:
$38.67
$42.19
52-Week Range:
$37.12
$103.81
Procept Biorobotics Corp Stock (PRCT) Company Profile
Name
Procept Biorobotics Corp
Sector
Industry
Phone
(650) 232-9832
Address
150 BAYTECH DRIVE, SAN JOSE
Compare PRCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRCT
Procept Biorobotics Corp
|
41.23 | 2.26B | 249.12M | -90.19M | -88.21M | -1.70 |
|
ABT
Abbott Laboratories
|
132.59 | 226.73B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.17 | 152.69B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
394.22 | 145.89B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.71 | 118.91B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
81.83 | 45.97B | 5.69B | 1.41B | 577.90M | 6.95 |
Procept Biorobotics Corp Stock (PRCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Initiated | Stephens | Overweight |
| Jul-07-25 | Initiated | Oppenheimer | Perform |
| Dec-02-24 | Initiated | Morgan Stanley | Overweight |
| Nov-14-24 | Initiated | Jefferies | Hold |
| Aug-11-23 | Initiated | Piper Sandler | Overweight |
| May-31-23 | Initiated | William Blair | Outperform |
| Oct-31-22 | Initiated | BTIG Research | Neutral |
| Oct-25-22 | Initiated | Truist | Buy |
| Sep-02-22 | Initiated | Wells Fargo | Overweight |
| Jul-15-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Jun-23-22 | Initiated | B. Riley Securities | Buy |
| Oct-11-21 | Initiated | BofA Securities | Buy |
| Oct-11-21 | Initiated | Cowen | Outperform |
| Oct-11-21 | Initiated | Goldman | Neutral |
| Oct-11-21 | Initiated | Guggenheim | Buy |
| Oct-11-21 | Initiated | SVB Leerink | Outperform |
View All
Procept Biorobotics Corp Stock (PRCT) Latest News
PROCEPT BioRobotics Corporation Attempts Reversal From Key SupportJuly 2025 Update & Fast Entry and Exit Trade Plans - classian.co.kr
PROCEPT BioRobotics Independent Director Acquires 2.4% More Stock - 富途牛牛
Overvalued Healthcare Tech Stocks: How Predictive Models Can Anticipate Market Corrections—A Case Study of PROCEPT BioRobotics (PRCT) - AInvest
Why PROCEPT BioRobotics (PRCT) Is Up 8.3% After Raising 2025 Revenue Guidance - simplywall.st
PROCEPT BioRobotics Corporation Shows Risk Reward Favoring Upside2025 Year in Review & Accurate Entry and Exit Point Alerts - 선데이타임즈
Why PROCEPT BioRobotics Corporation stock attracts strong analyst attentionAnalyst Upgrade & Entry and Exit Point Strategies - sundaytimes.kr
Director’s Bold Move: Major Investment in PROCEPT BioRobotics - TipRanks
Procept BioRobotics: A High-Growth Buy with Strengthening Pricing Power and Global Expansion Momentum - AInvest
Procept BioRobotics: Boosting Average Selling Price, Initiates Buy Rating - AInvest
Procept BioRobotics: Increasing Average Selling Price, Initiate At Buy (NASDAQ:PRCT) - Seeking Alpha
PROCEPT BioRobotics 15min chart: RSI Oversold, KDJ Golden Cross detected. - AInvest
Leerink Partners Reiterates a Buy Rating on PROCEPT BioRobotics (PRCT) - MSN
PROCEPT BioRobotics (PRCT) Guides Higher on Q2 Revenue Beat and Narrowing Losses – What Signals Ahead? - simplywall.st
Procept BioRobotics Grows Fast Despite Wall Street Skepticism - Finimize
PROCEPT BioRobotics Reports Strong Q2 2025 Growth - TipRanks
Why PROCEPT BioRobotics Shares Are Tumbling - TipRanks
Procept Biorobotics Reports Strong Q2 Growth Amid Challenges - TipRanks
PROCEPT BioRobotics outlines $325.5M 2025 revenue target amid leadership transition and margin expansion - MSN
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Q2 2025 Earnings Call Transcript - MSN
What You Can Learn From PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S After Its 34% Share Price Crash - simplywall.st
Procept Biorobotics Corp.’s Aquablation Therapy: A Promising Update for Prostate Cancer Treatment - The Globe and Mail
Edwards’ Longtime TAVR Leader is Named PROCEPT BioRobotics CEO - Medical Product Outsourcing
A Quick Look at Today's Ratings for PROCEPT BioRobotics(PRCT.US), With a Forecast Between $55 to $83 - 富途牛牛
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported, And Analysts Assigned A US$65.75 Price Target - simplywall.st
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT), Amgen (AMGN) and Qiagen (QGEN) - The Globe and Mail
PROCEPT BioRobotics 2025 Q2 Earnings Improved Losses Amid Revenue Surge - AInvest
PROCEPT BioRobotics Posts Q2 2025 Earnings: Revenue Up 48%, Net Loss Narrows by 24% - AInvest
PROCEPT BioRobotics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Buy Rating for PROCEPT BioRobotics: Growth Potential and Stability Amid Sales Beat and Improved Guidance - TipRanks
Procept BioRobotics' Q2 Revenue Jumps 48%, Exceeds Estimates - AInvest
PROCEPT BioRobotics Reports 48% YoY Revenue Growth in Q2 2025 - AInvest
Procept Biorobotics shares fall 13.46% intraday despite increased revenue guidance for 2025. - AInvest
A Quick Look at Today's Ratings for PROCEPT BioRobotics(PRCT.US), With a Forecast Between $85 to $85 - 富途牛牛
Earnings call transcript: Procept BioRobotics Q2 2025 beats forecasts, stock dips By Investing.com - Investing.com South Africa
Earnings call transcript: Procept BioRobotics Q2 2025 beats forecasts, stock dips - Investing.com
Truist Lowers Price Target on PROCEPT BioRobotics to $64 From $70, Keeps Buy Rating - MarketScreener
Wells Fargo lowers Procept BioRobotics stock price target on delayed system replacements - Investing.com Canada
Optimistic Outlook on PROCEPT BioRobotics Amidst Medtech Sector Challenges - TipRanks
PROCEPT BioRobotics (PRCT): Assessing the Path to Profitability Amid Leadership Transition and Global Expansion - AInvest
PROCEPT BioRobotics Sets $325.5M 2025 Revenue Target Amid Leadership Change and Margin Expansion - AInvest
Transcript : PROCEPT BioRobotics Corporation, Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Procept (PRCT) Q2 Revenue Jumps 48% - The Globe and Mail
Procept (PRCT) Q2 Revenue Jumps 48% - The Motley Fool
PROCEPT BioRobotics (PRCT) Earnings Transcript - Mitrade
Procept Biorobotics shares fall 3.72% after-hours despite Q2 revenue up 48% and raised 2025 guidance. - AInvest
Procept Biorobotics earnings beat by $0.06, revenue topped estimates - Investing.com South Africa
PROCEPT BioRobotics Corporation (PRCT) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Zimmer Biomet (ZBH) Q2 Revenue Jumps 7% - AOL.com
PROCEPT BioRobotics Q2 revenue up 48% YoY to $79.2mln. - AInvest
PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results - TradingView
Procept Biorobotics Corp Stock (PRCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Procept Biorobotics Corp Stock (PRCT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MOLL FREDERIC H | Director |
Aug 13 '25 |
Buy |
39.26 |
20,000 |
785,138 |
863,159 |
| Nouri Alaleh | EVP, CLO, CORP. SEC. |
Aug 14 '25 |
Option Exercise |
4.52 |
11,000 |
49,720 |
72,473 |
| Desai Antal Rohit | Director |
Jun 10 '25 |
Sale |
63.91 |
25,000 |
1,597,711 |
64,363 |
| Desai Antal Rohit | Director |
Jun 11 '25 |
Sale |
63.38 |
25,000 |
1,584,525 |
39,363 |
| Desai Antal Rohit | Director |
Jun 12 '25 |
Sale |
61.49 |
25,000 |
1,537,256 |
14,363 |
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):